@article{b318fc2b74c24b73962c45609a9c37f7,
title = "Management of prostate cancer in older patients: Updated recommendations of a working group of the International Society of Geriatric Oncology",
abstract = "In 2010, the International Society of Geriatric Oncology (SIOG) developed treatment guidelines for men with prostate cancer who are older than 70 years old. In 2013, a new multidisciplinary SIOG working group was formed to update these recommendations. The consensus of the task force is that older men with prostate cancer should be managed according to their individual health status, not according to age. On the basis of a validated rapid health status screening instrument and simple assessment, the task force recommends that patients are classed into three groups for treatment: healthy or fit patients who should have the same treatment options as younger patients; vulnerable patients with reversible impairment who should receive standard treatment after medical intervention; and frail patients with non-reversible impairment who should receive adapted treatment.",
author = "Droz, {Jean Pierre} and Matti Aapro and Lodovico Balducci and Helen Boyle and {Van den Broeck}, Thomas and Paul Cathcart and Louise Dickinson and Eleni Efstathiou and Mark Emberton and Fitzpatrick, {John M.} and Axel Heidenreich and Simon Hughes and Steven Joniau and Michael Kattan and Nicolas Mottet and St{\'e}phane Oudard and Heather Payne and Fred Saad and Toru Sugihara",
note = "Funding Information: J-PD has received honoraria from Novartis (conferences), from Sanofi (conferences and board meetings) and from Amgen (conferences). MA has received grants for research support from Helsinn, Merck, Perre Fabre, Sandoz, and Vifor; received honoraria and has participated in company sponsored speaker's bureaus for Amgen, Bayer Schering, BMS, Celgene, Cephalon, Chugai, Genomic Health, GSK, Helsinn, Hospira, Ipsen, Johnson and Johnson, Merck, Merck Serono, Novartis, Pfizer, Pierre Fabre, Roche, Sandoz, Sanofi, Teva, and Vifor. HB has received travel grants and honoraria from Sanofi and Janssen. LD has received funding from SonaCare Medical for clinical trials, medical consultancy, and travel to conferences. ME has been a consultant to Sanofi, GSK, Advanced Medical Diagnostics, Sonatherm, and Nuada Medical. JMF received honoraria from Sanofi, Janssen, Astellas, Takeda Pharmaceuticals, and Millennium. SH has been an invited speaker at advisory boards (Sanofi, Pfizer, Janssen, AstraZeneca, Pierre Fabre, and Astellas), received conference/meeting sponsorship (Sanofi and Astellas), and research collaborations (Alliance Medical, Cancer Research UK, Ipsen, and VisionRT). MK has been a consultant for Merck and GSK. NM has received grants or research support (Takeda Pharmaceutical/Millennium, Astellas, Pierre Fabre, Sanofi, and Pasteur) and honoraria or consultation fees (Takeda Pharmaceutical/Millennium, Janssen, Astellas, BMS, IPSEN, Ferring, Novartis, Pierre Fabre, Sanofi, and AstraZeneca). SO has received honoraria from and been a consultant for Sanofi, BMS, Roche, Janssen, Bayer, and Medivation. HP has received honoraria for advisory boards, travel expenses for medical meetings, and served as a consultant for AstraZeneca, Astellas, Janssen, Sanofi, Takeda, Amgen, Ipsen, Ferring and Novartis; and her research is supported by UCLH/UCL Comprehensive Biomedical Research Centre. FS has been a consultant and received research funding from Amgen, Novartis, Astellas, Janssen, Sanofi, and Millennium. LB, PC, EE, AH, SJ, TVdB, and TS declare no competing interests. Editorial support was provided by Julie Gray and Charlotte Ball from Adelphi Communications, and funded by the SIOG. ",
year = "2014",
month = aug,
doi = "10.1016/S1470-2045(14)70018-X",
language = "English (US)",
volume = "15",
pages = "e404--e414",
journal = "The lancet oncology",
issn = "1470-2045",
publisher = "Lancet Publishing Group",
number = "9",
}